|
1
|
Varadhachary GR and Raber MN: Cancer of
unknown primary site. N Engl J Med. 371:757–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qaseem A, Usman N, Jayaraj JS, Janapala RN
and Kashif T: Cancer of unknown primary: A review on clinical
guidelines in the development and targeted management of patients
with the unknown primary site. Cureus. 11:e55522019.PubMed/NCBI
|
|
3
|
Kato S, Alsafar A, Walavalkar V,
Hainsworth J and Kurzrock R: Cancer of unknown primary in the
molecular Era. Trends Cancer. 7:465–477. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavlidis N and Pentheroudakis G: Cancer of
unknown primary site. Lancet. 379:1428–1435. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pavlidis N, Khaled H and Gaafar R: A mini
review on cancer of unknown primary site: A clinical puzzle for the
oncologists. J Adv Res. 6:375–382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pavlidis N, Briasoulis E, Hainsworth J and
Greco FA: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hannouf MB, Winquist E, Mahmud SM,
Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS and Zaric GS:
The potential clinical and economic value of primary tumour
identification in metastatic cancer of unknown primary tumour: A
population-based retrospective matched cohort study. Pharmacoecon
Open. 2:255–270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang H, He F, Xu W and Cao Z: Clinical
features of cancer with unknown primary site (clinical features,
treatment, prognosis of cancer with unknown primary site). BMC
Cancer. 22:13722022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hainsworth JD, Rubin MS, Spigel DR, Boccia
RV, Raby S, Quinn R and Greco FA: Molecular gene expression
profiling to predict the tissue of origin and direct site-specific
therapy in patients with carcinoma of unknown primary site: A
prospective trial of the Sarah Cannon research institute. J Clin
Oncol. 31:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greco FA, Lennington WJ, Spigel DR and
Hainsworth JD: Molecular profiling diagnosis in unknown primary
cancer: Accuracy and ability to complement standard pathology. J
Natl Cancer Inst. 105:782–790. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Varadhachary GR, Talantov D, Raber MN,
Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, et
al: Molecular profiling of carcinoma of unknown primary and
correlation with clinical evaluation. J Clin Oncol. 26:4442–4448.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hayashi H, Kurata T, Takiguchi Y, Arai M,
Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, et
al: Randomized phase II trial comparing site-specific treatment
based on gene expression profiling with carboplatin and paclitaxel
for patients with cancer of unknown primary site. J Clin Oncol.
37:570–579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moran S, Martínez-Cardús A, Sayols S,
Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H,
Diaz-Lagares A, de Moura MC, et al: Epigenetic profiling to
classify cancer of unknown primary: A multicentre, retrospective
analysis. Lancet Oncol. 17:1386–1395. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laprovitera N, Salamon I, Gelsomino F,
Porcellini E, Riefolo M, Garonzi M, Tononi P, Valente S, Sabbioni
S, Fontana F, et al: Genetic characterization of cancer of unknown
primary using liquid biopsy approaches. Front Cell Dev Biol.
9:6661562021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pauli C, Bochtler T, Mileshkin L,
Baciarello G, Losa F, Ross JS, Pentheroudakis G, Zarkavelis G,
Yalcin S, Özgüroğlu M, et al: A challenging task: Identifying
patients with cancer of unknown primary (CUP) According to ESMO
Guidelines: The CUPISCO trial experience. Oncologist. 26:e769–e779.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pisacane A, Cascardi E, Berrino E,
Polidori A, Sarotto I, Casorzo L, Panero M, Boccaccio C, Verginelli
F, Benvenuti S, et al: Real-world histopathological approach to
malignancy of undefined primary origin (MUO) to diagnose cancers of
unknown primary (CUPs). Virchows Arch. 482:463–475. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uchikura E, Fukuda T, Imai K, Yamauchi M,
Kasai M, Ichimura T, Yasui T, Kuwae Y and Sumi T: Carcinomatous
meningitis from ovarian serous carcinoma: A case report. Oncol
Lett. 25:662022.PubMed/NCBI
|
|
18
|
Papanicolaou GN: Atlas of Exfoliative
Cytology. Cambridge, Mass: Harvard University Press; 1954
|
|
19
|
Hinata M, Kunita A, Abe H, Morishita Y,
Sakuma K, Yamashita H, Seto Y, Ushiku T and Fukayama M: Exosomes of
epstein-barr virus-associated gastric carcinoma suppress dendritic
cell maturation. Microorganisms. 8:17762020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
WHO Classification of Tumours Editorial
Board, . Female Genital Tumors, WHO Classification of Tumors. Vol
4:(5th edition). 2020.
|
|
21
|
Pereira TC, Saad RS, Liu Y and Silverman
JF: The diagnosis of malignancy in effusion cytology: A pattern
recognition approach. Adv Anat Pathol. 13:174–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Milbury CA, Creeden J, Yip WK, Smith DL,
Pattani V, Maxwell K, Sawchyn B, Gjoerup O, Meng W, Skoletsky J, et
al: Clinical and analytical validation of FoundationOne® CDx, a
comprehensive genomic profiling assay for solid tumors. PLoS One.
17:e02641382022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
González-Martín A, Pothuri B, Vergote I,
DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D,
Hoskins P, Freyer G, et al: Niraparib in patients with newly
diagnosed advanced ovarian cancer. N Engl J Med. 381:2391–2402.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coleman RL, Fleming GF, Brady MF, Swisher
EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat
Ben-Baruch N, Werner TL, et al: Veliparib with first-line
chemotherapy and as maintenance therapy in ovarian cancer. N Engl J
Med. 381:2403–2415. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Olivier T, Fernandez E, Labidi-Galy I,
Dietrich PY, Rodriguez-Bravo V, Baciarello G, Fizazi K and
Patrikidou A: Redefining cancer of unknown primary: Is precision
medicine really shifting the paradigm? Cancer Treat Rev.
97:1022042021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conway AM, Mitchell C, Kilgour E, Brady G,
Dive C and Cook N: Molecular characterisation and liquid biomarkers
in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’.
Br J Cancer. 120:141–153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kazanov L, Ander DS, Enriquez E and Jaggi
FM: Pseudo-Meigs' Syndrome. Am J Emerg Med. 16:404–405. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gücer F, Oz-Puyan F, Mülayim N and Yüce
MA: Ovarian dysgerminoma associated with Pseudo-Meigs' syndrome and
functioning ovarian stroma: A case report. Gynecol Oncol.
97:681–684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coutinho AE and Chapman KE: The
anti-inflammatory and immunosuppressive effects of glucocorticoids,
recent developments and mechanistic insights. Mol Cell Endocrinol.
335:2–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cristescu R, Mogg R, Ayers M, Albright A,
Murphy E, Yearley J, Sher X, Lin XQ, Lu H, Nebozhyn M, et al:
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based
immunotherapy. Science. 362:eaar35932018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park J, Lee JY and Kim S: How to use
immune checkpoint inhibitor in ovarian cancer? J Gynecol Oncol.
30:e1052019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leary A, Tan D and Ledermann J: Immune
checkpoint inhibitors in ovarian cancer: Where do we stand? Ther
Adv Med Oncol. 13:175883592110398992021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ward JP, Gubin MM and Schreiber RD: The
role of neoantigens in naturally occurring and therapeutically
induced immune responses to cancer. Adv Immunol. 130:25–74. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Raghav KP, Stephen B, Karp DD, Piha-Paul
SA, Hong DS, Jain D, Chudy Onwugaje DO, Abnofal A, Willett AF,
Overman M, et al: Efficacy of pembrolizumab in patients with
advanced cancer of unknown primary (CUP): A phase 2 non-randomized
clinical trial. J Immunother Cancer. 10:e0048222022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tanizaki J, Yonemori K, Akiyoshi K, Minami
H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y,
et al: Open-label phase II study of the efficacy of nivolumab for
cancer of unknown primary. Ann Oncol. 33:216–226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haratani K, Hayashi H, Takahama T,
Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita
Y, et al: Clinical and immune profiling for cancer of unknown
primary site. J Immunother Cancer. 7:2512019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Japanese government, . Act on the
Protection of Personal Information: Last Version: Act No. 37 of
2021. Translated Date: November 5, 2021. https://www.japaneselawtranslation.go.jp/ja/laws/view/130July
24–2023
|
